SYK vs. ABT, ISRG, BSX, MDT, BDX, EW, DXCM, IDXX, RMD, and STE
Should you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.
Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Stryker has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.
Stryker has a net margin of 16.03% compared to Abbott Laboratories' net margin of 13.65%. Stryker's return on equity of 23.05% beat Abbott Laboratories' return on equity.
In the previous week, Abbott Laboratories had 29 more articles in the media than Stryker. MarketBeat recorded 38 mentions for Abbott Laboratories and 9 mentions for Stryker. Stryker's average media sentiment score of 0.87 beat Abbott Laboratories' score of 0.64 indicating that Stryker is being referred to more favorably in the media.
Stryker pays an annual dividend of $3.20 per share and has a dividend yield of 1.0%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.1%. Stryker pays out 36.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Stryker currently has a consensus price target of $372.05, suggesting a potential upside of 12.18%. Abbott Laboratories has a consensus price target of $120.70, suggesting a potential upside of 14.70%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Stryker.
Abbott Laboratories received 28 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.69% of users gave Abbott Laboratories an outperform vote while only 64.46% of users gave Stryker an outperform vote.
77.1% of Stryker shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 5.9% of Stryker shares are owned by insiders. Comparatively, 1.1% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Stryker beats Abbott Laboratories on 12 of the 20 factors compared between the two stocks.
Get Stryker News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free SYK Stock Alerts